Please enable JavaScript or talk to your local administrator to get JavaScript enabled.

Project

Refined phenotyping and personalized targeting of muscle-invasive bladder cancer

Funder: Swiss National Science Foundation

Funding period
CHF 692 K
USD 709 K
Funding amount
Abstract
Bladder cancer is a lethal disease and half of patients with MIBC will succumb to their disease despite optimal therapy. Molecular subtypes of MIBC provides a framework for the understanding of the biology of this disease and these subtypes show differences in response to systemic treatments (e.g. to cisplatin or novel targeted therapies). We discovered genomic test, that determines the molecular subtype in a single patient tumor. This allows us to select tumors with a specific molecular subtype for further investigation. In this proposal, we aim to characterize patient derived models for the investigation of tumors of specific molecular subtypes. Furthermore, we will determine whether the investigation of the genomic landscape of bladder cancer specimens allow to predict treatment response. This proposal will serve as proof of concept, that molecular profiles allow to determine the molecular phenotype of the subsequent patient derived models and to predict their responsiveness in a personalized manner.
Similar projects All >
Sorted by: Start Date
Project list item
Characterization of Nectin-4 expression in molecular subtypes of urothelial cancer and mechanisms of resistance to enfortumab vedotin

Bladder Cancer Advocacy Network to Carissa Ellen Chu

USD 1,700
2020 - 2020
Project list item
Epigenetic regulators of subtype plasticity in bladder cancer

Bladder Cancer Advocacy Network to John Robert Christin

USD 1,700
2020 - 2020
Project list item
Defining NRF2 induced tumor invasion in bladder cancer

Bladder Cancer Advocacy Network to Yuki Kita, William Youngkwan Kim, Bernard Weissman

USD 50,000
2020 - 2021
Project list item
Targeting regulatory B cells (Bregs) to improve anti-bladder cancer immunity

Bladder Cancer Advocacy Network to Burles Avner Johnson, David McConkey

USD 50,000
2020 - 2021

System

Categories
  • FOR (ANZSRC)

    1112 Oncology and Carcinogenesis

  • RCDC

    Biotechnology

  • RCDC

    Human Genome

  • RCDC

    Cancer

  • RCDC

    Clinical Research

  • RCDC

    Genetics

  • RCDC

    Urologic Diseases

  • HRCS HC

    Cancer

  • HRCS RAC

    2.1 Biological and endogenous factors

  • Health Research Areas

    Biomedical

  • Broad Research Areas

    Clinical Medicine and Science